Advertisement

HIV Care Today


Ten Years After Landmark HIV Testing Guidelines, How Are We Doing? Specifically in Emergency Departments?
By Paul E. Sax, M.D.
September 18, 2016

In the late 1990s, a patient was admitted to our hospital with HIV-associated PCP. He had advanced AIDS, a CD4 cell count < 100, and was sick enough to require a temporary stay in our ICU.

Those clinical details aren't so remarkable -- "late" diagnoses of HIV still happen, and happened even more back then. What's remarkable is what happened to him before he got admitted.

Read more …


My Transition Toward Trans Awareness
By Robert M. Grant, M.D., M.P.H.
September 7, 2016

I recall when a colleague told me in 2014 that some transgender women advocates were unhappy with iPrEx. I was surprised and disappointed. Since the study was conceived in 2004, I had struggled to include trans women for so many reasons and against so many objections.

Read more …


The Most Common Question About the New HIV Testing Algorithm, Answered
By Paul E. Sax, M.D.
September 4, 2016

A 28yo woman had a positive 4th gen +Ag/Ab assay, but a negative HIV-1/2 differentiation assay and negative HIV viral load. She had no signs of acute HIV, but is not using condoms with her partner, whose HIV status she doesn't know. We repeated the test yesterday and she is again Ag/Ab+, the remainder of the test is pending. If we get the same results again, would you try to get a Western blot?

Read more …


Really Rapid Review -- AIDS 2016, Durban
By Paul E. Sax, M.D.
July 24, 2016

The International AIDS Conference returned this year to Durban, South Africa, where it was famously first held in 2000. At that time the HIV epidemic was exploding in South Africa; funding for HIV treatment was essentially non-existent, and there was ongoing HIV denialism quite openly from some very influential figures in the South African government (including the President). Globally, fewer than 1 million people were receiving antiretroviral therapy, hardly any of them in Africa.

Read more …


Must-Read Item: This Year's JAMA HIV/AIDS Issue
By Paul E. Sax, M.D.
July 14, 2016

The folks over at the Journal of the American Medical Association have been doing a periodic HIV/AIDS themed issue for years, generally around the time of the International AIDS Conference. The latest issue is out this week, and it's terrific.

Read more …


Velpatasvir/Sofosbuvir Makes HCV Treatment Simpler, Especially for Genotypes 2 and 3
By Paul E. Sax, M.D.
July 3, 2016

One of the ways ID and hepatology hepatitis C experts like to show off is by discoursing on the nuances of cleverly named clinical trials, and how these impact treatment guidelines.

Read more …


Drug Prior Authorizations Are a Very Blunt Tool for Cost Containment -- And They're Annoying
By Paul E. Sax, M.D.
May 22, 2016

Insurance prior authorizations, or prior approvals (PAs) -- those dreaded forms clinicians have to fill out, usually triggered by prescribing a non-formulary drug -- are much on my mind these days. And most of it has to do with three letters, specifically "TAF."

Read more …


Why Getting Old Isn't Always so Terrible -- and Why People With HIV Can Now Get Life Insurance
By Paul E. Sax, M.D.
April 24, 2016


Two patient-related anecdotes, then a news item.

Read more …


Zika and HIV: Connecting the Science
By Artur Timerman, M.D.
March 17, 2016

In my first years of medical practice, dealing with AIDS at that time was invariably fatal. Years later, still battling HIV, we are now faced with another outbreak of a similar nature -- the Zika virus. I remember the time when we did not have a clinical-epidemiological diagnosis of a new disease. I remember the era when we did not have a precise etiologic diagnosis. I remember a time when we had not yet discovered the virus responsible for AIDS. Pathogenesis was discussed by inferences but it took us four years to discover HIV (then HTLV-III or LAV) and even more time to understand how it caused immunodeficiency, although a lot still needs to be learned.

Read more …


Approval of TAF/FTC/RPV, Another Single Pill HIV Treatment Option
By Paul E. Sax, M.D.
March 9, 2016

The approval last week of TAF/FTC/RPV -- that's coformulated tenofovir alafenamide, emtricitabine, and rilpivirine -- brings us another one-pill, once-daily option for HIV treatment.

Read more …

 1  |  2  |  3  |  …  |  19  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.